For the second time in 16 months, Unity Biotechnology is restructuring its operations. The developer of drugs to treat diseases of aging is cutting its headcount in half to ensure its cash reserves ...
Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback